Kimberly Ellison
Family · Wytheville, VANPI 1205094174
Payments from drug & device makers
Across 117 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$387
- Alkermes, Inc.$262
- AbbVie$256
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$193
- Teva Pharmaceuticals USA, Inc.$182
- Otsuka America Pharmaceutical, Inc.$162
- plus $663 from 16 others
What the payments were for
- Food & beverage$2,02696%
- Education$784%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 21 | $387 |
| Alkermes, Inc. | 11 | $262 |
| AbbVie | 19 | $256 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $193 |
| Teva Pharmaceuticals USA, Inc. | 12 | $182 |
| Otsuka America Pharmaceutical, Inc. | 6 | $162 |
| AstraZeneca | 7 | $114 |
| Vanda Pharmaceuticals Inc. | 3 | $93 |
| Novo Nordisk | 6 | $87 |
| Neurocrine Biosciences, Inc. | 4 | $71 |
| Abbott | 2 | $42 |
| Lilly USA, LLC | 2 | $34 |
| Amgen | 2 | $27 |
| Novartis | 2 | $27 |
| Merck | 2 | $26 |
| Biohaven Pharmaceuticals, Inc. | 2 | $26 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| GSK | 2 | $24 |
| Genentech USA, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
How this compares
$2,104 in reported general payments places this provider in the 80th percentile of 4,332 family providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DayvigoLemborexant | 12 | $3,884 |
| Clozapine | 14 | $611 |
| Prazosin Hcl | 20 | $346 |
| Gabapentin | 45 | $180 |
| Mirtazapine | 15 | $178 |
| Buspirone Hcl | 12 | $172 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 17 | $161 |
| Lamotrigine | 21 | $133 |
| Benztropine Mesylate | 28 | $128 |
| Trazodone Hcl | 23 | $126 |
| Escitalopram Oxalate | 20 | $124 |
| Olanzapine | 16 | $102 |
| Risperidone | 15 | $93 |
| Diazepam | 13 | $49 |
| Quetiapine Fumarate | 14 | $37 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCOlanzapine | $34 | $10216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,332 family providers in Virginia.
Other family in Wytheville
- Susan MooreWytheville$438K
- Tara ParksWytheville$13K
- Andrea CottonVirginia Beach$696K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
- Adam MedlinHampton$67K
- Casey SharpDanville$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.